Search research articles
Contact Us
Filters
Showing results (221-230 of 381) with videos related to
Page
of 39
Sort By:
Leukemia
|
April 13, 2022
The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Haematologica
|
February 15, 2024
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study
Verónica González-Calle, Paula Rodríguez-Otero, Anna Sureda, et al.
Blood Cancer Journal
|
December 5, 2019
Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis
Nirav N Shah, Kwang Woo Ahn, Carlos Litovich, et al.
Haematologica
|
April 22, 2006
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study
Javier de la Rubia, Joan Bladé, Juan-José Lahuerta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2008
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy
Gema Mateo, M Angeles Montalbán, Maria-Belén Vidriales, et al.
Blood
|
September 8, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma
Lorenzo Falchi, Anna Sureda, Sirpa Leppä, et al.
Leukemia
|
July 15, 2022
Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Blood Advances
|
March 4, 2026
OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMT
Nicole Santoro, Jarl Eduard Mooyaart, Urban Novak, et al.
Hemasphere
|
February 26, 2026
Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working Party
Evgenii Shumilov, Maud Ngoya, Philipp Berning, et al.
Transplantation and Cellular Therapy
|
December 28, 2022
Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas
Alberto Mussetti, Abraham S Kanate, Tao Wang, et al.
Page
of 39
Search research articles
Search
Showing results (221-230 of 381) with videos related to
Sort By:
Page
of 39
Leukemia
|
April 13, 2022
The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Haematologica
|
February 15, 2024
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study
Verónica González-Calle, Paula Rodríguez-Otero, Anna Sureda, et al.
Blood Cancer Journal
|
December 5, 2019
Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis
Nirav N Shah, Kwang Woo Ahn, Carlos Litovich, et al.
Haematologica
|
April 22, 2006
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study
Javier de la Rubia, Joan Bladé, Juan-José Lahuerta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2008
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy
Gema Mateo, M Angeles Montalbán, Maria-Belén Vidriales, et al.
Blood
|
September 8, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma
Lorenzo Falchi, Anna Sureda, Sirpa Leppä, et al.
Leukemia
|
July 15, 2022
Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Blood Advances
|
March 4, 2026
OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMT
Nicole Santoro, Jarl Eduard Mooyaart, Urban Novak, et al.
Hemasphere
|
February 26, 2026
Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working Party
Evgenii Shumilov, Maud Ngoya, Philipp Berning, et al.
Transplantation and Cellular Therapy
|
December 28, 2022
Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas
Alberto Mussetti, Abraham S Kanate, Tao Wang, et al.
Page
of 39